AOU Integrata Verona Oncology Unit

AOU Integrata Verona

Carcinoma

Pathologic Constriction

Aortic Valve Stenosis

Renal Cell Carcinoma

Recurrence

Covidien

Elypta

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this trial is to generate clinical evidence on valve safety and performance of self-expanding (SE) versus balloon-expandable (BE) transcatheter aortic valve replacement (TAVR) in subjects with a small aortic annulus and symptomatic severe native aortic stenosis.

Additionally, a stress echocardiography sub-study will be conducted as part of the SMART Trial at select sites. The purpose of the sub-study is to evaluate performance of SE versus BE TAVR in subjects with a small aortic annulus and symptomatic severe native aortic stenosis after undergoing exercise stress echocardiographic testing.

SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial

AOU Integrata Verona | AOU Integrata Verona Oncology Unit

Site insights

Work at this site?

Active trials

SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial (SMART)

Trial sponsors